German diagnostic imaging outfit nanoPET Pharma is teaming up with Boehringer Ingelheim to develop diagnostic agents for preclinical drug development, building on a previous relationship between the two companies and opening the door for future collaboration.
Patients are overconfident in their ability to operate drug delivery medical devices and may not realize that they are using them incorrectly, a comprehensive survey by the U.K.'s Team Consulting shows.
Boehringer Ingelheim's Ofev and Roche's Esbriet became the first two U.S.-approved treatments for idiopathic pulmonary fibrosis when the FDA green-lighted them on the same day last month. And while Roche has the lead with Esbriet in Europe, Boehringer is now one step closer to leveling the playing field on the continent.
The safety message on Boehringer Ingelheim's key product, Pradaxa, has been mixed. But the German drugmaker has rolled out some new studies that show its effectiveness, as well as some promising data about the antidote being developed to treat serious bleeding in Pradaxa patients.
Boehringer Ingelheim is working with managed care giant WellPoint in an effort to use real-world data to inform the development of new treatments of atrial fibrillation, keeping up with a sweeping trend in cardiovascular R&D.
One drug. Two new safety studies promoted on the same day. Two different conclusions. That's the situation with Pradaxa, the Boehringer Ingelheim anticoagulant that's drawn scrutiny for reports of serious bleeding--and prompted safety reviews in the U.S. and EU
In a bit of a turnabout, Boehringer Ingelheim has landed a buyer from China for a U.S. plant it was closing even as it is building up its manufacturing operations in China.
Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has now given it a thumbs up after the FDA and the European regulators did the same thing this year.
About 240 workers at a Boehringer Ingelheim complex in Virginia will have something special to celebrate this Thanksgiving: the prospect of keeping their jobs. Just weeks ahead of closing the facility and laying off all its workers, Boehringer has found a Chinese buyer that intends to add to the headcount there.
Boehringer Ingelheim has completed a pilot project to assess whether it is best served by its current electronic laboratory notebook technology. The process led to Boehringer deciding to phase out use of multiple in-house systems and replace them with IDBS' E‑WorkBook Suite.